Company dossier

Vimta Labs Limited

NSE: VIMTALABS/Healthcare/Small Cap
Latest quarter
Q1 FY2027
Signal
BULLISH
Confidence
73%
Coverage
Full dossier
Sector
Healthcare
Market cap
Small Cap
Exchange
NSE
Research readiness
86%6/7 layers ready
Profile
Healthcare
Results
1 quarter report
Analysis
Double-digit YoY growth is constructive, while flat sequential revenue and capacity returns still need proof.
Orders
No order/capex signal mapped
Management
No management note linked
Policy/Macro
2 read-throughs
Evidence
1 linked source
Next actions
Map NSE/BSE filing signals
01/

Current pulse

Signal engine

Pattern-matched earnings signal

Double-digit revenue, PBT and PAT growth support a positive result read. HOLD reflects flat sequential growth, a softer operating margin excluding other income, higher depreciation and missing utilization, order-book and cash-flow evidence.

Evidence set
9 matched signals
Direction
BULLISH
Action
HOLD
Confidence
73%
Horizon
30D
Primary pattern

Double-digit YoY growth is constructive, while flat sequential revenue and capacity returns still need proof.

Key risk

New laboratory capacity can raise depreciation before utilization and revenue mature.

Next catalyst

Q1 FY2027 earnings call

02/

Dossier map

Pulse
IN LINE

Double-digit YoY growth is constructive, while flat sequential revenue and capacity returns still need proof.

Results
Q1 FY2027

Revenue ₹109.074 Cr | PAT ₹21.042 Cr | EBIT margin 37.7%

Order Book / Capex / Pipeline
TO STRUCTURE

This layer will track order book, execution runway, capex, capacity and pipeline as company-specific fields are populated.

Management
0 interviews

Management commentary and tone shift will sit here.

Policy + Macro
WATCH

Healthcare needs explicit government, rates, commodity, FX and demand sensitivity mapping.

Evidence
1 sources

New laboratory capacity can raise depreciation before utilization and revenue mature.